Thanksgiving 2023: Thankful for our customers and team | eBlog

As we come towards the end of the year, we at Eclipsebio are taking time this Thanksgiving holiday to reflect on what we are grateful for. As we have asked our fellow team members what they are thankful for, two topics have come up again and again: our customers who are performing groundbreaking RNA research and the team at Eclipsebio who continuously pushes the envelope on RNA genomics solutions. 

Every year our customers astonish us with how they apply our technologies to get fundamental insights into RNA biology and to develop novel life-saving therapeutics. 2023 was no exception, some of the publications from this year include: Corina Antal et al. used our RBP-eCLIP assay to get a deeper understanding of pancreatic cancer1, Adrienne Samani et al. used miR-eCLIP to identify microRNA targets involved in skeletal muscle disease2, and Matthew Mackeown et al. used eSHAPE to determine the structure of a viral 5’ UTR and its function in translational regulation3. We are also extremely thankful to our industry partners who have told us how data from our assays is invaluable and insightful for their drug development programs4,5

We are very grateful to our fellow team members: for those of us who have been with us from the start to our most recent hires. Our team has launched 3 new full-service solutions this year: 

eSHAPE: our optimized SHAPE-MaP assay for RNA structure profiling that can be used to identify accessible regions for therapeutic targeting, such as confirming on target binding and screening for off target binding
eRibo Pro: our optimzied Ribo-Seq assay for ribosome profiling, which can be used to identify therapeutic effects on transcription and translation within the same assay
miR-eCLIP +siRNA: our siRNA profiling service that allows for the direct validation of on-target and identification of off-target siRNA binding 

We are also thankful for our teams’ work to continuously improve procedures that ensure our customers get the best possible service with the fastest turnaround times possible, launching of a new educational initiative with our first global webinar and this blog series, and their involvement in our local San Diego community with volunteer events. 

Here’s to the years ahead of accelerating the development of tomorrow’s key RNA genomics discoveries and medicines. 

The Eclipsebio Team

References:
1. Antal et al. Nature Communications 
2. Samani et al. Life Science Alliance 
3. Mackeown et al. Journal of Biological Chemistry 
4. Ribometrix 
5. Alnylam Pharmaceuticals 

Related articles

eBlogs

02
26
24

Successful mRNA therapeutic design: optimizing for stability and translation | eBlog

mRNA therapeutics have unlocked the potential for rapid responses to infectious disease, personalized treatments for cancer, and protein replacement for different diseases. To ensure efficacy, specific features need to be included in the therapeutic to promote stability, efficient translation, and to... [READ MORE]

read more

eBlogs

01
30
24

How to find stalled ribosomes | eBlog

Monitoring translation dynamics at the gene level can be effectively achieved by employing ribosome profiling techniques, such as Eclipsebio’s eRibo Pro technology...[READ MORE]

read more

eBlogs

12
21
23

2023: A Year-in-Review | eBlog

2023 has been an exciting year for RNA and Eclipsebio! The RNA genomics space experienced a number of successes—from fascinating publications to the Nobel Prize in Physiology or Medicine, the importance of RNA to biology and health continues to be... [READ MORE]

read more

eBlogs

12
07
23

How to Use IGV: Part II | Bioinformatics eBlog

Next-generation sequencing (NGS) libraries produced by Eclipsebio’s assays typically consist of reads derived from targeted RNA regions. A visualization tool allows you to see which genes are present in your samples of interest and, depending on the assay, which specific transcript regions are enriched...[READ MORE]

read more